|
| 37643903 | Impact of Risk Factors on COVID-19 Outcomes in Unvaccinated People With Rheumatic Diseases: A Comparative Analysis of Pandemic Epochs Using the COVID-19 Global Rheumatology Alliance Registry. | Arthritis Care Res (Hoboken) | 2024 |
| 37992515 | Is glucocorticoid bridging therapy associated with later use of glucocorticoids and biological DMARDs during the disease course of patients with rheumatoid arthritis in daily practice? A real-world data analysis. | Semin Arthritis Rheum | 2024 |
| 35274588 | NT-proBNP and sRAGE levels in early rheumatoid arthritis. | Scandinavian Journal of Rheumatology | 2023 |
| 35833317 | Presence of SARS-CoV-2 antibodies in patients with COVID-19 like symptoms from the IENIMINI cohort. | Scandinavian Journal of Rheumatology | 2023 |
| 35441683 | The effect of silver fibre gloves on Raynaud's phenomenon in patients with systemic sclerosis: a double-blind randomized crossover trial. | Rheumatology | 2023 |
| 35470979 | High Prevalence but Low Impact of Cognitive Dysfunction on Quality of Life in Patients With Lupus and Neuropsychiatric Symptoms. | Arthritis Care and Research | 2023 |
| 36418483 | Glycobiology of rheumatic diseases. | Nature reviews. Rheumatology | 2023 |
| 36403538 | Autoreactive B cell responses targeting nuclear antigens in systemic sclerosis: Implications for disease pathogenesis. | Seminars in Arthritis and Rheumatism | 2023 |
| 37607810 | Initial glucocorticoid bridging in rheumatoid arthritis: does it affect glucocorticoid use over time? | | 2023 |
| 37744048 | The long-term course of the Health Assessment Questionnaire in patients with systemic sclerosis. | | 2023 |
| 37979961 | Long-term mortality in treated-to-target RA and UA: results of the BeSt and IMPROVED cohort. | | 2023 |
| 37788903 | IgM antibodies against acetylated proteins as a possible starting point of the anti-modified protein antibody response in rheumatoid arthritis. | | 2023 |
| 38053459 | Antibodies against advanced glycation end-products and malondialdehyde-acetaldehyde adducts identify a new specific subgroup of hitherto patients with seronegative arthritis with a distinct clinical phenotype and an HLA class II association. | | 2023 |
| 37087459 | The trajectory of clinical responses in patients with early rheumatoid arthritis who achieve sustained remission in response to abatacept: subanalysis of AVERT-2, a randomized phase IIIb study. | | 2023 |
| 36514807 | The Role of Genetics in Clinically Suspect Arthralgia and Rheumatoid Arthritis Development: A Large Cross-Sectional Study. | Arthritis Rheumatol | 2023 |
| 37028816 | Step forward in early recognition of systemic sclerosis: data from the Leiden CCISS cohort. | | 2023 |
| 36890568 | Geo-epidemiology of autoantibodies in rheumatoid arthritis: comparison between four ethnically diverse populations. | | 2023 |
| 36823186 | Author Correction: Glycobiology of rheumatic diseases. | | 2023 |
| 36702529 | Unmet need in rheumatology: reports from the Advances in Targeted Therapies meeting, 2022. | | 2023 |
| 36943357 | Comment on: Glucocorticoids prescribing practices in systemic sclerosis: an analysis of the EUSTAR database. | | 2023 |
| 36480251 | IgG Fab Glycans Hinder FcRn-Mediated Placental Transport. | | 2023 |
| 36869251 | Sustained Remission and Outcomes with Abatacept plus Methotrexate Following Stepwise Dose De-escalation in Patients with Early Rheumatoid Arthritis. | | 2023 |
| 37185308 | Repair of joint damage in patients with rheumatoid arthritis does not relate to previous suppression of inflammation: a subanalysis after 8 years treat-to-target in the BeSt-trial. | | 2023 |
| 36996012 | Whole body insulin sensitivity is increased in systemic sclerosis. | | 2023 |
| 36746531 | Progression from suspected to definite systemic sclerosis and the role of anti-topoisomerase I antibodies. | | 2023 |
| 36743815 | Mouth opening in systemic sclerosis: Its course over time, determinants and impact on mouth handicap. | | 2023 |
| 37436748 | Response to Biologic Drugs in Patients With Rheumatoid Arthritis and Antidrug Antibodies. | | 2023 |
| 36737098 | Clinical outcome in patients with suspected inflammatory neuropsychiatric lupus treated with immunosuppression: an observational cohort study. | | 2023 |
| 36927851 | Patterns of clinical joint inflammation in juvenile idiopathic arthritis. | | 2023 |
| 36609354 | Frequency of joint inflammation is associated with local joint damage progression in rheumatoid arthritis despite long-term targeted treatment. | | 2023 |
| 36725768 | Clinical Efficacy of Sarilumab Versus Upadacitinib Over 12Â weeks: An Indirect Treatment Comparison. | | 2023 |
| 37507206 | Anti-topoisomerase, but not anti-centromere B cell responses in systemic sclerosis display active, Ig-secreting cells associated with lung fibrosis. | | 2023 |
| 37480150 | Anti-carbamylated protein antibodies in systemic sclerosis. | | 2023 |
| 36526336 | Individual patient data meta-analysis on continued use of glucocorticoids after their initiation as bridging therapy in patients with rheumatoid arthritis. | | 2023 |
| 34996858 | To treat or not to treat with immunosuppressive therapy: psychiatric disorders in patients with systemic lupus erythematosus. | Lupus Science and Medicine | 2022 |
| 36371234 | Efficacy of belimumab combined with rituximab in severe systemic lupus erythematosus: study protocol for the phase 3, multicenter, randomized, open-label Synbiose 2 trial. | Trials | 2022 |
| 35450955 | Autoantibodies against specific post-translationally modified proteins are present in patients with lupus and associate with major neuropsychiatric manifestations. | RMD Open | 2022 |
| 35387864 | SARS-CoV-2 breakthrough infections among vaccinated individuals with rheumatic disease: results from the COVID-19 Global Rheumatology Alliance provider registry. | RMD Open | 2022 |
| 35583256 | ACPA-negative and ACPA-positive RA patients achieving disease resolution demonstrate distinct patterns of MRI-detected joint-inflammation. | Rheumatology | 2022 |
| 35579094 | Health-related quality of life in patients with mixed connective tissue disease: a comparison with matched systemic sclerosis patients. | Clinical and Experimental Rheumatology | 2022 |
| 36336400 | Comprehensive overview of autoantibody isotype and subclass distribution. | Journal of Allergy and Clinical Immunology | 2022 |
| 36333501 | Multi-ancestry genome-wide association analyses identify novel genetic mechanisms in rheumatoid arthritis. | Nat Genet | 2022 |
| 35871815 | Intervention with methotrexate in patients with arthralgia at risk of rheumatoid arthritis to reduce the development of persistent arthritis and its disease burden (TREAT EARLIER): a randomised, double-blind, placebo-controlled, proof-of-concept trial. | Lancet, The | 2022 |
| 35416963 | In rheumatoid arthritis patients, total IgA1 and IgA2 levels are elevated: implications for the mucosal origin hypothesis. | Rheumatology | 2022 |
| 35547229 | <i>Rheumatic</i>?-A Digital Diagnostic Decision Support Tool for Individuals Suspecting Rheumatic Diseases: A Multicenter Pilot Validation Study. | Front Med (Lausanne) | 2022 |
| 36259604 | Improvement of microangiopathy after haematopoietic stem cell transplantation in systemic sclerosis. | Clinical and Experimental Rheumatology | 2022 |
| 35470162 | Systematic literature review of observational cohorts and clinical trials into the success rate of glucocorticoid discontinuation after their use as bridging therapy in patients with rheumatoid arthritis. | Annals of the Rheumatic Diseases | 2022 |
| 36585217 | Baseline serum levels of cross-linked carboxy-terminal telopeptide of type I collagen predict abatacept treatment response in methotrexate-naive, anticitrullinated protein antibody-positive patients with early rheumatoid arthritis. | | 2022 |
| 36494508 | Tract-based white matter hyperintensity patterns in patients with systemic lupus erythematosus using an unsupervised machine learning approach. | | 2022 |
| 32471904 | Increasing incidence of autoantibody-negative RA is replicated and is partly explained by an aging population. | Annals of the Rheumatic Diseases | 2022 |